Table 1.
Baseline characteristics of dabigatran patients included in the study
| Dabigatran patients with available time of initiation (n=1240) | |
| Age (mean, SD) (median, IQR) | 75±10 (69–82) |
| Gender (N, %, female) | 656 (52.9) |
| NIHSS baseline (median, IQR) | 10 (6–16) |
| SBP (mm Hg, mean, SD) | 153±23 |
| DBP (mm Hg, mean, SD) | 85±15 |
| Glucose (mmol/dL, mean, SD) | 7.3±2.3 |
| Weight (kg, mean, SD) | 78±15 |
| Hypertension (N, %) | 955 (77) |
| Diabetes (N, %) | 216 (17.4) |
| Hyperlipidemia (N, %) | 349 (28.1) |
| Previous TIA (N, %) | 65 (5.3) |
| Current smoker (N, %) | 88 (7.1) |
| Previous smoker (N, %) | 107 (8.8) |
| Congestive heart failure (N, %) | 134 (10.9) |
| Vascular disease (N, %) | 149 (12) |
| Renal impairment (N, %) | 30 (2.6) |
| Abnormal liver function (N, %) | 16 (1.4) |
| Alcohol use (N, %) | 37 (3.2) |
| History of/predisposition to bleeding (N, %) | 30 (2.6) |
| Labile INR (N, %) | 39 (3.5) |
| Previous AF (N,%) | 720 (58.6) |
| Previous modified Rankin Scale (median, IQR) | 0 (0–0) |
| Previous CHA2DS2-VASc (mean) (median, IQR) |
3.1 3 (2–4) |
| Previous HAS-BLED (mean) (median, IQR) |
1.7 1 (1–2) |
| CHA2DS2-VASc discharge (mean) (median, IQR) |
5.1 5 (4–6) |
| HAS-BLED discharge (mean) (median, IQR) |
2.7 3 (2–3) |
| IVT (N, %) | 1055 (85.1) |
| EVT (N, %) | 68 (5.5) |
| IVT+EVT (N, %) | 117 (9.4) |
AF, atrial fibrillation; DBP, diastolic blood pressure; EVT, endovascular thrombectomy; INR, International Normalised Ratio; IVT, intravenous thrombolysis; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure; TIA, Transient Ischemic Attack.